摘要
目的分析菊明降压丸联合苯磺酸氨氯地平治疗原发性高血压的临床疗效。方法将本院心内科2015年8月~2016年10月收治的原发性高血压患者126例进行分组治疗,各63例。对照组给予苯磺酸氨氯地平治疗,观察组联合菊明降压丸治疗,分析2组降压疗效和对相关因子的影响以及安全性。结果 （1）观察组的总有效率为95.24%,高于对照组80.95%（P〈0.05）。（2）治疗后观察组收缩压（SBP）和舒张压（DBP）[分别为（128.5±6.3）、（78.4±5.2）mmHg]均低于对照组[（140.2±7.5）、（88.7±5.5）mmHg]（均P〈0.05）。（3）治疗后,观察组血浆一氧化氮（NO）和血清内皮素（ET）[分别为（70.16±5.51）μmol/L、（66.24±5.40）ng/L],均优于对照组[（64.16±5.33）μmol/L、（73.05±5.68）ng/L]（均P〈0.05）。（4）对照组出现11.11%的不良反应,高于观察组4.76%,但组间差异无统计学意义。结论菊明降压丸联合苯磺酸氨氯地平对于原发性高血压患者有更佳的疗效,且用药安全。
Objective To analyse clinical effects of Juming Jiangya pill combined with amlodipine besylate in treatment of essential hypertension.Methods 126 patients with essential hypertension from August 2015 to October 2016 were grouped two groups and each with 63 cases. The control group were treated with amlodipine besylate,and observation group was treated with Juming Jiangya pill. The effect of 2 groups of antihypertensive treatment,the influence on related factors and the safety were analyzed. Results（ After treatment,total effective rate of observation group was 95. 24%,higher than that of control group 80. 95%（ P〈 0. 05）.（ After treatment,SBP and DBP level of observation group[were（ 128. 5 ± 6. 3）,（ 78. 4 ± 5. 2） mmHg],lower than that of control group[（ 140. 2 ± 7. 5）,（ 88. 7 ± 5. 5） mmHg]（ all P 〈0. 05）.（3）After treatment,plasma NO and serum ET level of observation group were[（ 70. 16 ± 5. 51） μmol/L,（ 66. 24 ± 5. 40） ng/L],better than that of control group [（ 64. 16 ± 5. 33） μmol/L,（ 73. 05 ± 5. 68） ng/L） ]（ all P 〈0. 05）.（4）During treatment,proportion of adverse reactions of control group was 11. 11%,higher than that of observation group 4. 76%,difference was not statistically significant. Conclusion Juming Jiangya pill combined with amlodipine besylate have better curative effect and medication safety.
出处
《中国生化药物杂志》
CAS
2017年第7期101-103,共3页
Chinese Journal of Biochemical Pharmaceutics
